GAVI facts and figures

in page functions
[French]

Statistics measuring the GAVI Alliance's impact on global immunisation

Every year, academics, journalists, teachers and students ask for statistics detailing GAVI's results since the Alliance was established in 2000. Sourcing the GAVI Secretariat and members of the Alliance, including WHO, UNICEF and civil society organisations, these key facts and figures list GAVI's achievements to date as well as demonstrating the Alliance's catalytic role within global immunisation.

US$ 80-100 billion

Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

Source: Stack M et al. Estimated economic benefits during Decade of Vaccines, Health Affairs 2011

+ 150 million
 

By the end of 2013, 11 countries in the African meningitis belt had collectively immunised 153 million people against meningitis A with support from the Vaccine Alliance.

Source: WHO/UNICEF

+60

For 2013, more than 60 countries were co-financing new and underused vaccines supplied by the Vaccine Alliance. Their contributions totalled US$ 70 million.

Source: Gavi

24%

In total, 24% of children in Gavi-supported countries are not being vaccinated.

Source: WHO/UNICEF

70%

70% of cervical cancer cases can be prevented with human papillomavirus vaccines. One woman dies from cervical cancer every two minutes - or 275,000 a year - over 85% in the developing world.

Source: WHO

6 million

Approximately six million future deaths averted from hepatitis B, Haemophilus influenzae type B, measles, pertussis, pneumococcal disease, polio, rotavirus diarrhoea and yellow fever since Gavi's launch in 2000.

Source: Gavi/Bill & Melinda Gates Foundation

440 million
 

Since 2000, 440 million children have been immunised through Gavi support to routine immunisation in the world's poorest countries.

Source: WHO-UNICEF

11 million
 

Gavi support had contributed to immunising 11 million children against pneumococcal disease by the end of 2013.

Source: WHO/UNICEF

+243,000,000

Gavi support will assist countries to immunise a further 243 million children between 2011 and 2015.

Source: Gavi

73 countries
 

Gavi support is available to the 73 poorest countries in the world. By the end of 2013, 22 countries were projected to graduate from Gavi’s support by 2020.

Source: Gavi

US$ 8.7 billion

By the end of June 2014, the Vaccine Alliance had committed US$ 8.7 billion in programme support until 2017 to the world’s poorest countries.

Source: Gavi

3.9 million
 

Gavi support for vaccines will contribute to averting close to an estimated 3.9 million future deaths between 2011 and 2015.

Source: Gavi

+40%

Over the course of a decade, the weighted average price of pentavalent vaccine (DTP-hepB-Hib) dropped by 43% from US$ 3.56 per dose in 2003 to US$ 2.04 per dose in 2013, with a lowest-ever price of US$ 1.19 from one supplier in 2013.

Source: Gavi

1.5 million
 

In 2012, approximately 6.6 million children died before the age of five. WHO estimates that 1.5 million of these deaths are due to vaccine-preventable diseases.

Source: WHO

5 -> 13

2001: 5 vaccine suppliers to Gavi (one in a middle-income country) | 2013: 13 vaccine suppliers to Gavi (six based in middle-income countries) 

Source: UNICEF

22 million
 

Nearly 22 million [21.8 million] infants remain unimmunised in the world each year.

Source: WHO/UNICEF

close icon

modal window here